Dare2Think
Summary
Preventing stroke, premature eath and cognitive decline in a broader community of patients with atrial fibrillation using healthcare data for pragmatic research: A randomised controlled trial.
Using an efficient, nationwide, primary care approach for an NHS-embedded randomised controlled trial (RCT), does direct oral anticoagulant (DOAC) therapy reduce premature death, stroke and other thromboembolic consequences of atrial fibrillation (AF) in younger patients, including prevention of cognitive decline and vascular dementia.
For more information please click HERE for the full summary.
Further details can be viewed on the university's website.
Contact the team at mse.lehprimarycareresearch@nhs.net for the study protocol.
Sponsor - University of Birmingham
Recruitment End Date - 30/06/2025
Type of Study - Recruiting
RSI Points - 400
EMIS/CPRD Practices Only!
Practice Involvement
Review participant list in IRSP -Interventional Research Platform (CPRD)
Invite eligible participants
Informed consent
Randomise interested participants through IRSP
Prescribe DOAC for those randomised to that arm of the study
Report SAE’s in IRSP
Eligibility Criteria
Inclusion
Diagnosis of AF (previous, current or chronic)
Age at enrolment ≥55 years to ≤73 years
Exclusion
Subjects who meet any of the conditions detailed on the protocol. Please contact the team to receive the list of exclusion criteria.
***To express an interest for the Dare2Think study please use the form provided and a member of the team will be in touch***